Amy Shapiro, MD, medical director, Indiana Hemophilia and Thrombosis Center, discusses the clinical trials that influenced plasminogen's (Ryplazim; Kedrion Biopharma) FDA approval, as well as details valuable information for the treatment of patients with plasminogen deficiency.
Study results presented at the 2023 American Society of Hematology Annual Meeting and Exposition found equal immune tolerance induction success rates regardless of race/ethnicity.
Investigators address 2 questions: How can we better understand the biology of these rare disorders? How can we stimulate research and optimize the regulatory process to improve diagnosis and targeted treatment?
/PRNewswire/ - To ensure patient safety remains at the forefront of the work of the World Federation of Hemophilia (WFH), we have developed a registry to.
MONTREAL, Jan. 18, 2023 /PRNewswire/ To ensure patient safety remains at the forefront of the work of the World Federation of Hemophilia (WFH), we have developed a registry to monitor the